Jointown(SH:600998) Ge Long Hui A P P·2026-02-06 10:00Core Viewpoint - The approval of the listing application for Betahistine Dihydrochloride Tablets by the National Medical Products Administration is a significant milestone for the company, indicating potential growth in the neurology and cerebrovascular disease market [1] Group 1: Product Approval - The company's subsidiary, Beijing Jingfeng Pharmaceutical Group Co., Ltd., received the acceptance notice for the listing application of Betahistine Dihydrochloride Tablets on February 5, 2026 [1] - Betahistine Dihydrochloride is primarily used for Ménière's disease, vascular headaches, and cerebral arteriosclerosis, and is effective in treating acute ischemic cerebrovascular diseases [1] - The drug is classified as a Category A medication under the national medical insurance and is included in the national essential drug list, addressing the high demand for dizziness-related conditions amid an aging population [1] Group 2: Business Performance - The company is actively expanding its pharmaceutical manufacturing and OEM business, focusing on increasing product variety and quality to enhance market competitiveness [1] - In the first three quarters of 2025, the company's pharmaceutical manufacturing and OEM business achieved sales revenue of 2.3 billion yuan, representing a year-on-year growth of 9.93% [1] - Beijing Jingfeng Pharmaceutical reported a revenue of 431 million yuan in the same period, with a year-on-year increase of 12.48% [1]